S&P 500   3,011.18 (+0.15%)
DOW   26,827.36 (0.00%)
QQQ   194.26 (+0.45%)
AAPL   241.75 (+0.52%)
FB   189.70 (-0.03%)
MSFT   139.79 (+0.98%)
GOOGL   1,243.46 (-0.07%)
AMZN   1,779.05 (-0.37%)
CGC   20.39 (+0.20%)
NVDA   200.23 (+2.15%)
MU   45.54 (+0.71%)
BABA   173.93 (+0.24%)
GE   8.68 (-1.25%)
TSLA   252.98 (-0.21%)
AMD   31.84 (-0.59%)
T   37.84 (-1.02%)
F   8.99 (-0.44%)
ACB   3.64 (-1.36%)
PRI   125.09 (-0.49%)
NFLX   273.32 (-1.70%)
BAC   30.83 (-0.61%)
GILD   65.72 (+0.78%)
DIS   132.97 (+2.08%)
S&P 500   3,011.18 (+0.15%)
DOW   26,827.36 (0.00%)
QQQ   194.26 (+0.45%)
AAPL   241.75 (+0.52%)
FB   189.70 (-0.03%)
MSFT   139.79 (+0.98%)
GOOGL   1,243.46 (-0.07%)
AMZN   1,779.05 (-0.37%)
CGC   20.39 (+0.20%)
NVDA   200.23 (+2.15%)
MU   45.54 (+0.71%)
BABA   173.93 (+0.24%)
GE   8.68 (-1.25%)
TSLA   252.98 (-0.21%)
AMD   31.84 (-0.59%)
T   37.84 (-1.02%)
F   8.99 (-0.44%)
ACB   3.64 (-1.36%)
PRI   125.09 (-0.49%)
NFLX   273.32 (-1.70%)
BAC   30.83 (-0.61%)
GILD   65.72 (+0.78%)
DIS   132.97 (+2.08%)
Log in

Hikma Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:HKMPY)

$48.80
0.00 (0.00 %)
(As of 10/22/2019 08:49 AM ET)
Today's Range
$48.80
Now: $48.80
$48.80
50-Day Range
$48.80
MA: $48.80
$48.80
52-Week Range
$35.95
Now: $48.80
$52.40
VolumeN/A
Average Volume519 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HKMPY
CUSIPN/A
CIKN/A
Phone+44-20-73992760

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees8,400
Next Earnings DateN/A
OptionableNot Optionable

Receive HKMPY News and Ratings via Email

Sign-up to receive the latest news and ratings for HKMPY and its competitors with MarketBeat's FREE daily newsletter.


Hikma Pharmaceuticals (OTCMKTS:HKMPY) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPY."

What is the consensus analysts' recommendation for Hikma Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hikma Pharmaceuticals.

Has Hikma Pharmaceuticals been receiving favorable news coverage?

Headlines about HKMPY stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Hikma Pharmaceuticals earned a news impact score of 0.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include Intelsat (I), Associated British Foods (ABF), Chaarat Gold (CGH), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), First Data (FDC), tronc (TRNC), Apollo Global Management (APO) and China Unicom (Hong Kong) (CHU).

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)
  • Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 61)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPY stock can currently be purchased for approximately $48.80.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is http://www.hikma.com/.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.


MarketBeat Community Rating for Hikma Pharmaceuticals (OTCMKTS HKMPY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  43 (Thanks for Voting!)
Underperform Votes:  58 (Thanks for Voting!)
Total Votes:  101
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HKMPY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HKMPY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel